Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
DJ Humanigen的抗肿瘤Ifaotuzumab一期结果呈阳性
By Matt Grossman
马特·格罗斯曼(Matt Grossman)著
Humanigen Inc.'s ifabotuzumab drug achieved positive results in a Phase 1 safety and bio-imaging trial in patients with glioblatoma multiforme, the company said Friday.
Humanigen公司周五表示,该公司的ifobtuzumab药物在多形性胶质母细胞瘤患者的一期安全性和生物成像试验中取得了积极的结果。
Glioblatoma multiforme is a type of brain cancer.
多形性胶质母细胞瘤是一种脑癌。
At both doses in the study, ifabotuzumab showed sensitive and specific tumor targeting in all the patients who received it, Humanigen said. The adverse events in the study were readily manageable, the company said.
Humanigen说,在研究中的两种剂量下,ifobtuzumab在所有接受治疗的患者中都显示出敏感和特异的肿瘤靶向。该公司表示,研究中的不良事件很容易控制。
Andrew Scott, the study's principal investigator, said the results support further investigation of the drug's effect on other solid tumors in a Phase 2 study.
该研究的首席研究员安德鲁·斯科特(Andrew Scott)说,这一结果支持在第二阶段研究中进一步研究该药物对其他实体肿瘤的影响。
Write to Matt Grossman at matt.grossman@wsj.com
写信给马特·格罗斯曼(Matt Grossman),电子邮件:matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
April 09, 2021 07:27 ET (11:27 GMT)
2021年04月09日07:27(格林尼治标准时间11:27)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。